- Home
- ISPC vs ENVB Comparison
ISPC vs ENVB Comparison
Compare ISPC & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- ENVB
- Stock Information
- Founded
- ISPC 2009
- ENVB 1994
- Country
- ISPC United States
- ENVB United States
- Employees
- ISPC N/A
- ENVB N/A
- Industry
- ISPC Precision Instruments
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- ENVB Health Care
- Exchange
- ISPC Nasdaq
- ENVB Nasdaq
- Market Cap
- ISPC 4.7M
- ENVB 4.2M
- IPO Year
- ISPC 2021
- ENVB N/A
- Fundamental
- Price
- ISPC $3.86
- ENVB $0.33
- Analyst Decision
- ISPC
- ENVB Strong Buy
- Analyst Count
- ISPC 0
- ENVB 1
- Target Price
- ISPC N/A
- ENVB $10.00
- AVG Volume (30 Days)
- ISPC 213.0K
- ENVB 156.7K
- Earning Date
- ISPC 11-07-2024
- ENVB 11-14-2024
- Dividend Yield
- ISPC N/A
- ENVB N/A
- EPS Growth
- ISPC N/A
- ENVB N/A
- EPS
- ISPC N/A
- ENVB N/A
- Revenue
- ISPC $10,390,702.00
- ENVB N/A
- Revenue This Year
- ISPC $13.82
- ENVB N/A
- Revenue Next Year
- ISPC $11.76
- ENVB N/A
- P/E Ratio
- ISPC N/A
- ENVB N/A
- Revenue Growth
- ISPC 0.74
- ENVB N/A
- 52 Week Low
- ISPC $2.76
- ENVB $0.30
- 52 Week High
- ISPC $12.20
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- ISPC 35.78
- ENVB 40.19
- Support Level
- ISPC $2.76
- ENVB $0.34
- Resistance Level
- ISPC $4.66
- ENVB $0.37
- Average True Range (ATR)
- ISPC 0.40
- ENVB 0.03
- MACD
- ISPC -0.07
- ENVB 0.01
- Stochastic Oscillator
- ISPC 23.16
- ENVB 53.66
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.